Oncodesign

Foundation date

05/01/1995

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Oncodesign is a biopharma company dedicated to the precision medicine. Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB.

Upcoming events

Latest news

  • Mayne Pharma and Mithra announce FDA approval of HALOETTE®, a generic version of NUVARING®

    Monday August 8th 2022

  • S-Biomedic welcomes Pascal Yvon to lead its B2B commercial activities

    Tuesday August 2nd 2022

  • Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial

    Monday August 1st 2022